Versantis is a clinical-stage company developing transformative orphan drugs that fill the medical gap in the care of liver and pediatric diseases. The company is now advancing its lead candidate, VS-01, into a Phase 2a trial which will lead to pivotal registration trials in two orphan indications.
Products, services, technology
VS-01-ACLF phase 2a-ready; FDA orphan-designated in acute-on-chronic liver failure.
VS-01-UCD preclinical-stage; FDA orphan-designated in acute pediatric hyperammonemia.
VS-02 oral, small molecule for chronic hepatic encephalopathy (HE).
TS-01 point-of-care diagnostic device to manage HE at home
- http://www.versantis.ch
- +41 44 500 88 91
- vincent@versantis.ch
- Vincent Forster
